Wheeler v. Commissioner of Social Security Administration

CourtDistrict Court, N.D. Ohio
DecidedJanuary 25, 2024
Docket1:23-cv-00106
StatusUnknown

This text of Wheeler v. Commissioner of Social Security Administration (Wheeler v. Commissioner of Social Security Administration) is published on Counsel Stack Legal Research, covering District Court, N.D. Ohio primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Wheeler v. Commissioner of Social Security Administration, (N.D. Ohio 2024).

Opinion

UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF OHIO EASTERN DIVISION

SETH WHEELER, CASE NO. 1:23-CV-00106-DAC

Plaintiff, MAGISTRATE JUDGE DARRELL A. CLAY

vs. MEMORANDUM OPINION AND ORDER

COMMISSIONER OF SOCIAL SECURITY ADMINISTRATION,

Defendant.

INTRODUCTION Plaintiff Sean Wheeler challenges the Commissioner of Social Security’s decision denying disability insurance benefits (DIB) and supplemental security income (SSI). (ECF #1). The District Court has jurisdiction under 42 U.S.C. §§ 1383(c) and 405(g). On May 4, 2023, the parties consented to my exercising jurisdiction over this case pursuant to 28 U.S.C. § 636(c). (ECF #7). Following review, and for the reasons stated below, I AFFIRM the Commissioner’s decision. PROCEDURAL BACKGROUND Mr. Wheeler filed for DIB and SSI on January 28, 2021, alleging a disability onset date of May 14, 2020. (Tr. 232). The claims were denied initially and on reconsideration. (Tr. 91-124). Mr. Wheeler then requested a hearing before an Administrative Law Judge. (Tr. 152-53). Mr. Wheeler (represented by counsel) and a vocational expert (VE) testified before the ALJ on January 25, 2022. (Tr. 36-59). On February 9, 2022, the ALJ determined Mr. Wheeler was not disabled. (Tr. 16-35). The Appeals Council denied Mr. Wheeler’s request for review, making the hearing decision the final decision of the Commissioner. (Tr. 1-3; see 20 C.F.R. §§ 404.955, 404.981, 416.1455, and 416.1481). Mr. Wheeler timely filed this action on January 19, 2023. (ECF #1).

FACTUAL BACKGROUND I. PERSONAL AND VOCATIONAL EVIDENCE Mr. Wheeler was 25 years old on the alleged onset date, which the regulations define as a “younger individual.” (Tr. 30; 28 C.F.R. § 404.1563(c)). Mr. Wheeler completed high school but has no past relevant work. (Id.). II. RELEVANT MEDICAL EVIDENCE

Mr. Wheeler treated with psychiatric nurse practitioner Dawn Dunaway for medication management of his bipolar disorder and anxiety. (See., e.g., Tr. 1602-05). During his appointment on July 2, 2020, Mr. Wheeler reported he had stopped taking Neurontin and Elavil because he felt they were not helpful. (Tr. 1602). He reported feeling anxious and apathetic, and described his mood as irritable and lacking motivation. (Id.). He had been doing well before COVID, including working part-time although he found work too stressful, took time off, and never returned. (Id.). On examination, Mr. Wheeler was oriented in three spheres, and his memory, attention and

concentration, and judgment and insight were fair. (Id.). His affect was relaxed, speech was normal, and thought form was logical. (Id.). He denied hallucinations, suicidal or homicidal ideations. (Id.). NP Dunaway discontinued Elavil and Neurontin and started Mr. Wheeler on Depakote. (Tr. 1603). She recommended he follow up in two weeks. (Tr. 1604). On August 8, 2020, Mr. Wheeler attended a follow up session with NP Dunaway. (Tr. 1606). He reported being dizzy and “zoned out” on Trileptal and stopped taking it after a week; he was compliant with his 500 mg dose of Depakote. (Id.). His mood was anxious and irritable and wished to switch mood stabilizers. (Id.). On examination, Mr. Wheeler was oriented in three spheres; his memory, attention and concentration, and judgment and insight were fair. (Id.). His

affect was constricted, speech was normal, and thought form was logical. (Id.). He denied hallucinations, suicidal or homicidal ideations. (Id.). NP Dunaway discontinued Trileptal and Depakote and started Mr. Wheeler on Equetro 100 mg for two weeks and 200 mg thereafter. (Tr. 1607). He was assessed as having an unspecified anxiety disorder and bipolar disorder in full remission with most recent episode depressed. (Tr. 1608). She recommended he follow up in three weeks. (Id.).

At follow up on August 27, 2020, Mr. Wheeler reported that he felt “hung over” the next day on his new medication and would sometimes forget to take the second dose at the end of the day. (Tr. 1610). He did not notice a difference in mood and continued feeling angry. (Id.). On examination, Mr. Wheeler was oriented in three spheres, his memory, attention and concentration, and judgment and insight were fair. (Id.). His affect was constricted, speech was normal, and thought form was logical. (Id.). He denied hallucinations, suicidal or homicidal

ideations. (Id.). NP Dunaway started Mr. Wheeler on Lamictal and discontinued Equetro. (Tr. 1612). She recommended he follow up in four weeks. (Id.). On October 17, 2020, Mr. Wheeler reported he had stopped taking Lamictal; he was still feeling angry and was more tired. (Tr. 1614). He reported anxiety and a mild panic attack. (Id.). He wished to go back on Depakote. (Id.). On examination, Mr. Wheeler was oriented in three spheres, his memory, attention and concentration, and judgment and insight were fair. (Id.). His affect was

constricted, speech was normal, and thought form was logical. (Id.). He denied hallucinations, suicidal or homicidal ideations. (Id.). NP Dunaway discontinued Lamictal and started Mr. Wheeler on Klonopin 0.5 mg and Depakote 500 mg. (Tr. 1616). She recommended he follow up in four weeks. (Id.).

On November 14, 2020, Mr. Wheeler reported he took Klonopin at bedtime that helped his anxiety; he slept 7 to 12 hours at night but sometimes had nightmares. (Tr. 1618). He noticed no difference with Depakote and weaned himself off of it completely. (Id.). He still had anger episodes. (Id.). On examination, Mr. Wheeler was oriented in three spheres, his memory, attention and concentration, and judgment and insight were fair. (Id.). His affect was constricted, speech was normal, and thought form was logical. (Id.). He denied hallucinations, suicidal or homicidal

ideations. (Id.). NP Dunaway added Latuda 20 mg, continued Klonopin, and discontinued Depakote. (Tr. 1620-21). She recommended he follow up in two weeks. (Tr. 1620). At follow up on November 28, 2020, Mr. Wheeler reported that Latuda helped his anger but he still felt depressed. (Tr. 1622). He reported being unsure if the Klonopin was helping his depression, so he stopped taking it for a period; he determined he feels better with a half-pill of Klonopin but did not want to take it anymore. (Id.). He felt more motivated and considered

applying for jobs but was still pursuing disability benefits. (Id.). On examination, Mr. Wheeler was oriented in three spheres, his memory, attention and concentration, and judgment and insight were fair. (Id.). His affect was constricted, speech was normal, and thought form was logical. (Id.). He denied hallucinations, suicidal or homicidal ideations. (Id.). NP Dunaway noted improved interval progress and recommended he follow up in two weeks. (Tr. 1623-24). She added Xanax as needed, continued Latuda, and discontinued Klonopin. (Tr. 1624). On December 17, 2020, Mr. Wheeler reported that he felt “pretty good” and denied anger and irritability. (Tr. 1626). He was compliant with Latuda and took Xanax twice, reporting that Xanax tired him, relieved his anxiety, and did not cause mood changes like Klonopin. (Id.). On

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Wheeler v. Commissioner of Social Security Administration, Counsel Stack Legal Research, https://law.counselstack.com/opinion/wheeler-v-commissioner-of-social-security-administration-ohnd-2024.